Avid Bioservices

Avid Bioservices, Inc. engages in the commercial manufacturing. The firm focuses on the biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. It specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions and support. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Avid Bioservices Achieves Record Revenues, Faces Margin Challenges

Avid Bioservices achieved record revenues and strong bookings, but faced challenges with decreased gross margins and increased expenses. Moving into the viral vector space and with a strong late-phase project pipeline, the company sees opportunities for growth in the next 12 to 15 months.

Avid Bioservices reports Q2 earnings, focuses on expansion and innovation

Avid Bioservices showcased positive operational performance with increased utilization of the new mammalian line fleet and a record backlog. While facing challenges related to net loss and revenue recognition delays, the company remains focused on expansion and innovation, presenting opportunities for growth in the cell and gene therapy space and later-stage products.

Avid Bioservices reports robust Q3 earnings and targets pharma growth

Avid Bioservices delivered strong financial results in Q3 2023, showcasing revenue growth and operational efficiency.
While facing challenges in margins and expenses, the company's strategic focus on quality and growth presents opportunities for expansion.
With a solid cash position, record backlog, and targeted business development, Avid is poised for continued success in the market.

Avid Bioservices reports record revenues and backlog, eyes strategic growth

Avid Bioservices delivered a strong performance in Q4 2023, marked by record revenues and backlog, showcasing operational efficiency and market demand.
While facing challenges such as margin impact and resource allocation shifts, the company remains optimistic about its growth prospects and revenue stability.
Strategic opportunities lie in leveraging the strong backlog, cash flow, and planned CapEx to drive future growth and operational excellence.

Avid Bioservices reports revenue growth and expansion plans for 2024

Avid Bioservices' Q1 2024 performance reflects revenue growth and strategic investments in expanding capacity and capabilities.
While facing challenges in gross margins and profitability, the company's progress on the new facility signals future growth potential.
Opportunities lie in leveraging the completed facility to drive revenue, enhance market competitiveness, and address analyst concerns for improved performance.

Avid Bioservices reports record backlog and growth opportunities for 2024

Avid Bioservices showcased financial resilience with an improved cash position and strong backlog, despite facing revenue challenges. The company's focus on new services, customer diversity, and operational efficiency bodes well for future growth.

Avid Bioservices reports revenue growth and strategic expansions in Q3

Avid Bioservices reported strong revenue growth and backlog performance in Q3, while facing revenue decline and cost challenges compared to the previous year. Strategic expansions and operational refinements position the company for future opportunities in a competitive market landscape.

Avid Bioservices reports revenue growth and new projects, faces cost challenges

Avid Bioservices reported positive revenue growth and secured new project agreements, positioning the company for future expansion.
Despite challenges such as increased SG&A expenses and a net loss, Avid's focus on capacity utilization and new programs offers growth potential.
Addressing operational challenges and uncertainties while capitalizing on opportunities can drive Avid Bioservices towards improved financial performance.
The company's financial stability, strong backlog, and focus on profitability highlight a resilient business strategy amidst industry dynamics.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avid Bioservices, Inc. engages in clinical and commercial manufacturing of biologics. It focuses on the biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. It specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions and support. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.

Avid Bioservices (NASDAQ:CDMO) reported its Q2 earnings results on Tuesday, December 7, 2021 at 04:05 PM. Here's what investors need to know about the announcement.

Avid Bioservices: Q2 Earnings Insights

Avid Bioservices (NASDAQ:CDMO) is set to give its latest quarterly earnings report on Tuesday, 2021-12-07. Here's what investors need to know before the announcement.

Earnings Preview: Avid Bioservices

Bicycle Therapeutics Plc - ADR

BioNTech SE

Enanta Pharmaceuticals

IVERIC bio Inc

Moderna

Prothena

The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.

7 A-Rated Biotechs to Buy for the Long Run

Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Avid Bioservices (CDMO) Earnings Expected to Grow: What to Know Ahead of Q2 Release

Seasoned Life Science Industry Executive with More Than 30 Years of Experience in Cell and Gene Therapy, Including Senior Level Viral Vector Development Positions with Fujifilm Diosynth Biotechnologies and Millipore Sigma Seasoned Life Science Industry Executive with More Than 30 Years of Experience in Cell and Gene Therapy, Including Senior Level Viral Vector Development Positions with Fujifilm Diosynth Biotechnologies and Millipore Sigma

Avid Bioservices Appoints Elie G. Hanania, Ph.D.

The stock price of Avid Bioservices, a contract development and manufacturing company for biopharmaceutical products, has surged 48% in a month (twenty-one trading days), while it is up a solid 19% in a week. The recent rise can be attributed to CDMO's inclusion in the S&P SmallCap 600 index.

Will The Rally In Avid Bioservices Stock Continue After 48% Rise In A Month?

The stock will be part of a well-known index.

Why Avid Bioservices Stock Surged 14% Today

TUSTIN, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will be added to the S&P SmallCap 600 Index, effective prior to the open of trading on Friday, October 29, 2021.

Avid Bioservices to Join S&P SmallCap 600 Index

Leverages Established Track Record of Excellence in Biologics CGMP Manufacturing to Address the Rapidly Growing Cell and Gene Therapy Market

Avid Bioservices Announces Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy

Avid Bioservices (CDMO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 20.1% in 4 Weeks, Here's Why Avid Bioservices (CDMO) Looks Ripe for a Turnaround

Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q2 2021 Results - Earnings Call Transcript

Healthcare is one market no one can say is going to slow down, and so, many of the best investments lie within.

Avid Bioservices: FDA CGMP Stringency Provides Stable Long Outlook

Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biopharmaceutical Industry Experience Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biopharmaceutical Industry Experience

Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D.

Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q4 2021 Results - Earnings Call Transcript

-- Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million -- -- Achieved Four Consecutive Quarters of Operational Profitability During Fiscal 2021 --

Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments

TUSTIN, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year (FY) ended April 30, 2021 on June 29, 2021 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the quarter and FY ended April 30, 2021 and review recent corporate developments.

Avid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on June 29, 2021

Avid Bioservices (CDMO) Q4 Earnings Preview: What's in the Cards?

Bionano Genomics

VistaGen Therapeutics

BioCryst Pharmaceuticals

22nd Century Group

Investors in search of long-term growth are increasingly choosing biotech stocks like BNTX stock and MRNA stock for their portfolios. The post 7 A-Rated Biotech Stocks to Buy Now appeared first on InvestorPlace.

7 A-Rated Biotech Stocks to Buy Now

Avid Bioservices (CDMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Avid Bioservices (CDMO) Stock Jumps 7.2%: Will It Continue to Soar?

ZYNLONTA™ Recently Approved as First and Only CD19-Targeted Antibody Drug Conjugate for Single-Agent Treatment for Adult Patients with Relapsed or Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) ZYNLONTA™ Recently Approved as First and Only CD19-Targeted Antibody Drug Conjugate for Single-Agent Treatment for Adult Patients with Relapsed or Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL)

Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics' ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)

Agenus

Atossa Genetics

Cocrystal Pharma

Ocugen, Inc.

SIGA Technologies

Sio Gene Therapies

Small-cap stocks in the biotech space have been in a slump, but these seven companies could see big moves just around the corner. The post 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts appeared first on InvestorPlace.

7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts

As of late, it has definitely been a great time to be an investor in Avid Bioservices, Inc. (CDMO).

Avid Bioservices' (CDMO) Shares March Higher, Can It Continue?

Alphatec Hlds

Organogenesis Holdings

Healthcare has been lagging the market, but that is now changing. As biotechs consolidate, other healthcare industry groups are powering the sector to a breakout.

3 Healthcare Stocks As The Sector Breaks Out To New Highs

TUSTIN, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it has completed the redemption of all of the company's outstanding 10.50% Series E Convertible Preferred Stock (“Series E Preferred Stock”) as of April 12, 2021 (the “Redemption Date”).

Avid Bioservices Announces Completion of Redemption of Series E Convertible Preferred Stock

Amtech Systems

Aytu BioScience

Interactive Brokers

Oncternal Therapeutics Inc

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Interactive Brokers (IBKR), Avid (CDMO), Oncternal (ONCT), Amtech (ASYS) and Aytu.

News for Avid Bioservices Stock (CDMO)